Histogenics Corporation, a privately held, regenerative medicine company, today announced that President and Chief Executive Officer Patrick O’Donnell will present at the upcoming Canaccord Genuity Musculoskeletal Conference on February 7th at 3:30pm PT at the Parc 55 Wyndham in San Francisco. Mr. O’Donnell will discuss the Company’s lead product candidates, including NeoCart®, an autologous bioengineered neocartilage grown outside the body using the patient’s own cells for the regeneration of cartilage lesions and VeriCart™, a three-dimensional cartilage matrix to stimulate cartilage repair in a simple, one-step procedure. NeoCart recently entered a Phase 3 clinical trial and will be the subject of an oral presentation at the Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), which is also taking place in San Francisco from February 7th-11th.
About Histogenics
Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. In May of 2011, Histogenics acquired Israeli cell-therapy company Prochon BioTech. Histogenics’ flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility. The Company takes an interdisciplinary approach to engineering neocartilage that looks, acts and lasts like hyaline cartilage. It is developing new treatments for sports injuries and other orthopaedic conditions, where demand is growing for long-term alternatives to joint replacement. Histogenics has successfully completed Phase 1 and Phase 2 clinical trials of its NeoCart autologous tissue implant and is currently in a Phase 3 IND clinical study. Based in Waltham, Massachusetts, the company is privately held. For more information, visit www.histogenics.com.
